Cancer treatment may benefit from the discovery of a new peptide receptor radiolabled therapy (PRRT).
This is according to research from the Erasmus Medical Centre in The Netherlands, where doctors demonstrated an improvement in the quality of life of patients with rare neuroendocrine tumours.
These tumours have no cure but due to their slow grow rate life expectancy remains relatively high.
"We showed that the years gained after this therapy show an improved quality of life, as judged by the patients themselves," said the lead author of the study Dr Saima Khan.
During the research, 265 patients with neuroendocrine tumours were given PRRT and they recorded improvements on questionnaires.
PRRT was demonstrated to limit the side effects of the tumour and actually reduce its size. It also has no adverse effects unlike traditional chemotherapy treatments.
According to Cancer Research UK's latest figures, 309,500 people contracted some form of cancer in the UK in 2008.
© Adfero Ltd
Cancer treatment news : 22 September 2011